Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients

Hepatology International

Volumn 9, Issue 2, 2015, Pages 202-208

  Laohapand, Charlie ^a   Arromdee, Emvalee ^a   Tanwandee, Tawesak ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Chronic HBV; HBV reactivation; Hepatitis B; Methotrexate; Rheumatoid arthritis; Thailand

Indexed keywords

ANTIRHEUMATIC AGENT; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; METHOTREXATE; VIRUS DNA;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BLOOD; CHRONIC HEPATITIS B; CROSS-SECTIONAL STUDY; DRUG EFFECTS; FEMALE; GENETICS; HEPATITIS B VIRUS; HUMAN; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PHYSIOLOGY; SPONDYLARTHROPATHIES; TIME FACTOR; VIRUS ACTIVATION; VIRUS LOAD;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CROSS-SECTIONAL STUDIES; DNA, VIRAL; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METHOTREXATE; MIDDLE AGED; SPONDYLARTHROPATHIES; TIME FACTORS; VIRAL LOAD; VIRUS ACTIVATION;

EID: 84939962284     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-014-9597-6     Document Type: Article

References (22)

1. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003;23:47–58
2. McMahon BJ. The natural history of chronic hepatitis B virus infection. Semin Liver Dis 2004;24:17–21
3. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006;26:130–141
4. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335–352
5. Fattovich G, Olivari N, Pasino M, D’Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008;57:84–90
6. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:535–550
7. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652–657
8. Knoll A, Pietrzyk M, Loss M, Goetz WA, Jilq W. Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen: low risk of HBV reactivation. Transplantation 2005;79:1631–1633
9. Marcellin P, Giostra E, Martinot-Peignoux M, Loriot MA, Jaegle ML, Wolf P, et al. Redevelopment of hepatitis-B surface-antigen after renal-transplantation. Gastroenterology 1991;28:231–236
10. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy, report of a prospective study. Gastroenterology 1991;100:182–188
11. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 2006;4:1076–1081
12. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762–784
13. Flowers MA, Heathcote J, Wanless IR, Sherman M, Reynolds WJ, Cameron RG, et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low dose methotrexate therapy. Ann Intern Med 1990;112:381–382
14. Narvaéz J, Rodriguez-Moreno J, Martinez-Aguila MD, Clavaguera MT. Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. J Rheumatol 1998;25:2037–2038
15. Ito S, Nakazono K, Murasawa A, Mita Y, Hata K, Saito N, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001;44:339–342
16. Hagiyama H, Kubota T, Komano Y, Kurosaki M, Watanabe M, Miyasaka N. Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol 2004;22:375–376
17. Watanabe K, Takase K, Ohno S, Ideguchi H, Nozaki A, Ishigatsubo Y. Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate. Mod Rheumatol 2012;22:470–473
18. Chimparlee N, Oota S, Phikulsod S, Tangkijvanich P, Poovorawan Y. Hepatitis B and hepatitis C virus in Thai blood donors. Southeast Asian J Trop Med Public Health 2011;42:609–615
19. Srisupanant M, Wiwanitkit V. Prevalence of hepatitis B seropositivity among Thai workers in screening program before going abroad. Ann Hepatol. 2008;7:389
20. Chongsrisawat V, Yoocharoen P, Theamboonlers A, Tharmaphornpilas P, Warinsathien P, Sinlaparatsamee S, et al. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop Med Int Health 2006;11:1496–1502
21. Luksamijarulkul P, Kaepan W, Klamphakorn S. Hepatitis B virus sero-markers, hepatitis C virus antibody and risk behaviors among middle age and older Thai males. Southeast Asian J Trop Med Public Health 2007;38:45–52
22. Marignani M, Canzoni M, D’Amelio R, Santis ED, Pecchioli A, Fave GD. Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? No. Eur J Intern Med 2011;22:576–581